Medicalgorithmics reports 56.00 percent growth: Medicalgorithmics stock is worth PLN 250.8 million

Published on 10/05/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medicalgorithmics revenue reached PLN 10.9 million in the second quarter, up 56.00 percent year over year. Medicalgorithmics stock is valued at PLN 250.8 million.

Medicalgorithmics, PLMDCLG00015, Illustration mit AI erstellt.

Medicalgorithmics (PLMDCLG00015) reported 56.00 percent year-over-year revenue growth in the second quarter of 2026, while its stock is valued at PLN 250.8 million on October 5, 2026. Strefa Inwestorow reported on September 30, 2026 that the company combined higher sales with positive earnings before interest, taxes, depreciation and amortization.

Revenue reaches PLN 10.9 million

Medicalgorithmics generated consolidated sales revenue of PLN 10.9 million in the second quarter of 2026, compared with PLN 7.0 million in the second quarter of 2025. The resulting 56.00 percent increase gives the company a clear operating comparison against the same period a year earlier.

According to Bankier, the first-half 2026 report dated September 29, 2026 recorded PLN 21.083 million of consolidated sales revenue, versus PLN 13.739 million in the first half of 2025. The same report showed an operating loss of PLN 378,000 for the first half of 2026, compared with PLN 6.032 million in the first half of 2025.

Cash flow turns positive

The second-quarter operating picture also improved beyond revenue. Inwestycje.pl reported PLN 1.4 million of EBITDA in the second quarter of 2026, up 37.00 percent from the first quarter, while operating cash flow reached PLN 3.4 million, up 187.00 percent quarter over quarter. The company therefore delivered a third consecutive quarter of positive operating cash flow.

The US business contributed PLN 4.8 million of second-quarter revenue, an increase of 111.00 percent year over year. Medicalgorithmics also analyzed nearly 119,000 ECG tests during the period, linking the financial improvement to a larger operating base rather than a single reported contract.

US expansion supports the next step

The company extended its agreement with its largest customer in the United States by one year in August 2026. The renewed arrangement runs through July 15, 2028 and includes higher rates for completed sessions, according to Strefa Inwestorow.

Medicalgorithmics also signed a three-year agreement in August 2026 with a US technology company serving more than 300 clinical facilities. The company is using the DRAI and DRP platforms, while Medicalgorithmics is directing development funding toward VCAST, AI Vesper and Gimlet.

Warsaw listing and next report

Investing.com identifies Medicalgorithmics as ticker MDG on the Warsaw Stock Exchange and places its market capitalization at PLN 250.8 million as of October 5, 2026. The same page lists November 26, 2026 as the next earnings date, giving the market a defined checkpoint for the company's growth and cash-flow trajectory.